An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors

Overview

First in human, open-label, sequential dose escalation and expansion study of intravenous BAL101553 in adult patients with advanced solid tumors.

Full Title of Study: “An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients With Advanced Solid Tumors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2016

Interventions

  • Drug: BAL101553
    • Intravenous administration

Arms, Groups and Cohorts

  • Experimental: Drug: BAL101553 at MTD
  • Experimental: Drug: BAL101553 at 50% of MTD

Clinical Trial Outcome Measures

Primary Measures

  • To determine the maximum tolerated dose and characterize dose limiting toxicities of BAL101553
    • Time Frame: 28 day cycles
    • First-cycle dose limiting toxicities (DLT)

Secondary Measures

  • To evaluate safety and tolerability of BAL101553 treatment
    • Time Frame: 28 day cycles
    • Incidence of adverse events, laboratory abnormalities, clinically significant changes in vital signs or ECG assessments
  • To evaluate BAL101553 pharmacokinetics
    • Time Frame: 28 day cycles
    • BAL101553 and BAL27862 PK parameters including (but not limited to): Cmax (maximum observed plasma concentration), AUC (area under the concentration time curve), half-life, volume of distribution
  • To assess anti-tumor activity of BAL101553
    • Time Frame: 28 day cycles
    • Response rate per RECIST guidelines
  • To explore the use of biomarkers and to characterize pharmacodynamic effects of BAL101553
    • Time Frame: 28 day cycles
    • Exploratory assessment of baseline levels and change from baseline in the number of circulating tumor cells and other biomarkers

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥ 18 years 2. Patients with one of the following advanced or recurrent solid tumor types, who failed standard therapy or for whom no effective standard therapy is available:colorectal; gastric or cancers of the gastro-esophageal junction; non-small cell lung cancer; ovarian (or primary peritoneal); pancreatic (including ampullary); triple-negative breast 3. Measurable tumor disease (or non-measurable ovarian cancer that can be followed by CA-125) 4. Life expectancy ≥ 12 weeks 5. Acceptable organ and marrow function at baseline (protocol defined laboratory parameters) 6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 7. Other protocol-defined inclusion criteria may apply. Exclusion Criteria:

1. Patients who have received chemotherapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to starting study drug or who have not recovered from side effects of prior therapies 2. Symptomatic brain metastases (including leptomeningeal disease) indicative of active disease 3. Peripheral neuropathy ≥ CTCAE v4 grade 2 4. Uncontrolled intercurrent illness that would unduly increase the risk of toxicity or limit compliance with study requirements 5. Women who are pregnant or breast-feeding. Men or women of reproductive potential who are not willing to apply effective birth control 6. Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg observed as part of the screening examination. 7. Patients treated with a calcium channel blocker or who require combination of more than 2 antihypertensives to control blood pressure. 8. Other protocol-defined exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Basilea Pharmaceutica
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marc Engelhardt, MD, Study Director, Basilea Pharmaceutica International Ltd

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.